School project · Delayed data · Not financial adviceTerms
SingularityViewAll companies

Stock research

Eledon Pharmaceuticals, Inc. ELDN

Healthcare · Biotechnology

$2.48last close 2026-10-09 · market cap $201.53M · delayed data

Trailing returns

1M-12.06%
3M-39.95%
6M-20.00%
1Y-16.78%
5Y-58.49%

Basis: Adjusted daily closes.

What it does

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).

Open ELDN in the live terminal →

Valuation, cost of capital, SEC filings, ownership and more, with the source named on every figure.

Post on XLinkedInEmail

Where these figures come from

Delayed data. Not financial advice. Figures are read from the sources above at the dates shown; nothing here is a recommendation. Disclosures · All companies